Scientific Publications

R. Garcia-Carbonero, M. Gil Martín, R. Alvarez Gallego, T. Macarulla Mercade, M.C. Riesco Martinez, C. Guillen-Ponce, N. Vidal, F.X. Real, R. Moreno, V. Maliandi, A. Mato- Berciano, M. Bazan-Peregrino, G. Capella, R. Alemany, E. Blasi, C. Blasco, M. Cascallo, R. Salazar. “Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial”. Poster presented at Anual Meeting of the European Society of Medical Ooncology (ESMO) 2019, Barcelona (Spain).
ESMO2019 Poster MoA VCN-01 vFinal.pdf



R. Garcia-Carbonero, M. Gil Martín, R. Alvarez Gallego, T. Macarulla Mercade, M.C. Riesco Martinez, C. Guillen-Ponce, N. Vidal, F.X. Real, R. Moreno, V. Maliandi, A. Mato- Berciano, M. Bazan-Peregrino, G. Capella, R. Alemany, E. Blasi, C. Blasco, M. Cascallo, R. Salazar. “Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial”. Poster presented at Anual Meeting of the European Society of Medical Ooncology (ESMO) 2019, Barcelona (Spain).
ESMO 2019 Poster VCN-01 IV vFinal.pdf



Pascual-Pasto G, Bazan-Peregrino M, Mato-Berciano A, Correa G, Cuadrado-Vilanova M, Burgueño-Sandoval V, Alonso-Lopez P, Torres-Manjon S, Moreno R, Catalá-Mora J, Alemany R, Cascallo M, Chantada GL, Carcaboso AM. “VCN-01 is an encouraging therapy against retinoblastoma”. Oral Communication presented at International Oncolytic Virus Conference (IOVC) 2021, Sedona (US)
Retinoblastoma_IOVC_2021v1.pdf



Mato-Berciano A, Morgado S, Maliandi MV, Farrera-Sal M, Gimenez-Alejandre M, Ginestà MM, Moreno R, Torres-Manjon S, Moreno P, Arias-Badia M, Rojas LA, Capellà G, Alemany R, Cascallo M, Bazan-Peregrino M. “Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11” J Control Release 2021 Apr 10;332:517-528.
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11 - ScienceDirect



Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Álvarez R, Mato-Berciano A, Gimenez-Alejandre M, Morgado S, Rodríguez-García A, Maliandi MV, Riesco MC, Moreno R, Ginestà MM, Perez-Carreras M, Gornals JB, Prados S, Perea S, Capella G, Alemany R, Salazar R, Blasi E, Blasco C, Cascallo M, Hidalgo M “VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects” . J Immunother Cancer 2021;9:e003254.
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects (bmj.com)



Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D Weber K, Correa G, Paco S Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M König A, Suñol M, Claverol J, Lavarino, Carmen de T, Fu L13, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine  23 Jan 2019: Vol. 11, Issue 476, eaat9321. DOI: 10.1126/scitranslmed.aat9321 
https://stm.sciencemag.org/content/11/476/eaat9321.short



Vera B, Martínez-Vélez N, Xipell E, Acanda de la Rocha A, Patiño-García A, Saez-Castresana J, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01 . PLoS One. 2016 Jan 25;11(1)
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147211



Martínez-Vélez N, Xipell E, Vera B, Acanda de la Rocha A, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño A, Alonso MM. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Clin Cancer Res. 2016 May 1;22(9):2217-25
http://clincancerres.aacrjournals.org/content/22/9/2217.long



Rojas LA, Condezo GN, Moreno R, Fajardo CA, Arias-Badia M, San Martín C, Alemany R. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. J Control Release. 2016 Sep 10;237:78-88. doi: 10.1016/j.jconrel.2016.07.004. Epub 2016 Jul 4.
http://www.sciencedirect.com/science/article/pii/S0168365916304291



Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K. Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy . Mol Ther. 2015 Jan;23(1):108-18.
https://www.ncbi.nlm.nih.gov/pubmed/25352242



Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, Moreno R, Bazan-Peregrino M, Cascalló M, Alemany R. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015 Mar 15;21(6):1406-18. doi: 10.1158/1078-0432.CCR-14-2213. Epub 2014 Nov 12.
http://clincancerres.aacrjournals.org/content/21/6/1406.long

 

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. "Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth". Molecular Therapy vol. 18 no. 7, 1275–1283 (2010).
https://www.ncbi.nlm.nih.gov/pubmed/20442708



Gros A., Martínez-Quintanilla J. Puig C, Guedan S., Molleví D.G., Alemany R., Cascallo M. "Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency". Cancer Research 68(21): 8928-8937 (2008).
http://cancerres.aacrjournals.org/content/68/21/8928.long.